The Medicinal Chemicals and Botanical Products industry on FinBizNet covers 86 listed companies, with broker-view summaries, sub-industry segmentation, latest quarterly results and peer comparisons for each constituent.
| Listed companies | 86 |
|---|---|
| Combined market cap | ₹16,39,750 Cr |
| Median P/E (profitable companies) | 32.9 |
| Median return on equity | 10.2% |
| Companies with latest quarterly results | 65 of 86 |
| Company | Market Cap | P/E | ROE | Quarterly Revenue | Quarterly Net Profit | Quarter |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,21,995 Cr | 36.4 | 14.7% | ₹15,300 Cr | ₹2,911 Cr | Q1 FY27 |
| Zydus Lifesciences Ltd | ₹1,12,020 Cr | 22.2 | 18.3% | ₹8,017 Cr | ₹952 Cr | Q1 FY27 |
| Laurus Labs Ltd | ₹1,11,310 Cr | 125.3 | 17.7% | ₹2,026 Cr | ₹362 Cr | Q1 FY27 |
| Cipla Limited | ₹1,07,048 Cr | 27.6 | 11.7% | ₹7,119 Cr | ₹787 Cr | Q1 FY27 |
| Dr.Reddys Lab | ₹1,02,611 Cr | 24.1 | 11.5% | ₹8,698 Cr | ₹921 Cr | Q2 FY27 |
| Aurobindo Pharma Ltd. | ₹95,910 Cr | 26.8 | 9.9% | ₹9,150 Cr | ₹1,034 Cr | Q1 FY27 |
| Mankind Pharma | ₹93,977 Cr | 48.7 | 12.4% | ₹4,031 Cr | ₹570 Cr | Q1 FY27 |
| Lupin Ltd | ₹89,426 Cr | 16.6 | 26.9% | ₹8,277 Cr | ₹1,417 Cr | Q1 FY27 |
| Glenmark Pharmaceuticals Limited | ₹62,838 Cr | 45.7 | 14.1% | ₹4,018 Cr | ₹483 Cr | Q1 FY27 |
| Alkem Laboratories Ltd | ₹60,380 Cr | 25.9 | 17.6% | ₹3,740 Cr | ₹521 Cr | Q1 FY27 |
| Gland Pharma Limited | ₹50,206 Cr | 48.4 | 10.5% | ₹1,800 Cr | ₹317 Cr | Q1 FY27 |
| Ipca Laboratories Ltd. | ₹46,494 Cr | 40.5 | 13.2% | ₹2,788 Cr | ₹423 Cr | Q1 FY27 |
| J.B.Chemicals & Pharmaceuticals Ltd. | ₹38,731 Cr | — | 18.7% | ₹904 Cr | ₹101 Cr | Q4 FY26 |
| Wockhardt Ltd | ₹31,766 Cr | 145.4 | 4.0% | ₹929 Cr | ₹107 Cr | Q1 FY27 |
| Acutaas Chemicals Ltd | ₹26,248 Cr | 75.2 | 23.5% | ₹330 Cr | ₹75 Cr | Q1 FY27 |
| Neuland Laboratories Ltd. | ₹25,274 Cr | 67.7 | 21.4% | ₹642 Cr | ₹148 Cr | Q1 FY27 |
| Granules India Ltd | ₹20,461 Cr | 32.9 | 13.5% | ₹1,477 Cr | ₹180 Cr | Q1 FY27 |
| Shilpa Medicare Ltd. | ₹18,336 Cr | 70.7 | 9.8% | ₹466 Cr | ₹95 Cr | Q1 FY27 |
| Natco Pharma Ltd | ₹14,061 Cr | 10.1 | 16.9% | ₹735 Cr | ₹122 Cr | Q1 FY27 |
| Procter & Gamble Health Ltd | ₹8,641 Cr | 26.1 | 61.6% | ₹364 Cr | ₹96 Cr | Q1 FY27 |
| Symbiotec Pharmalab | ₹8,222 Cr | 65.6 | — | ₹218 Cr | ₹14 Cr | Q1 FY27 |
| Supriya Lifescience Limited | ₹7,131 Cr | 33.7 | 19.1% | ₹190 Cr | ₹24 Cr | Q1 FY27 |
| Morepen Laboratories Ltd. | ₹6,773 Cr | 70.9 | 7.8% | ₹570 Cr | ₹56 Cr | Q1 FY27 |
| Fdc Ltd. | ₹5,807 Cr | 19.9 | 11.8% | ₹668 Cr | ₹132 Cr | Q1 FY27 |
| Iol Chemicals & Pharmaceuticals Ltd. | ₹5,719 Cr | 39.0 | 7.9% | ₹756 Cr | ₹64 Cr | Q1 FY27 |
| Rpg Life Sciences Ltd. | ₹4,863 Cr | 40.8 | 20.3% | ₹196 Cr | ₹31 Cr | Q1 FY27 |
| Gujarat Themis Biosyn Ltd. | ₹4,843 Cr | 84.0 | 17.4% | ₹44 Cr | ₹11 Cr | Q1 FY27 |
| Jeena Sikho Lifecare Ltd | ₹4,827 Cr | 20.9 | 59.9% | ₹224 Cr | ₹66 Cr | Q1 FY27 |
| Orchid Pharma Ltd | ₹4,622 Cr | 538.6 | 0.7% | ₹304 Cr | ₹3 Cr | Q1 FY27 |
| Gufic Biosciences Ltd. | ₹4,043 Cr | 63.4 | 10.1% | ₹261 Cr | ₹22 Cr | Q1 FY27 |
Market data from the FinBizNet stock universe; quarterly figures in ₹ crore, parsed from each company's exchange filing (XBRL). Showing the 30 largest of 86 companies.
FinBizNet tracks 86 listed companies in the Medicinal Chemicals and Botanical Products industry, including Sun Pharmaceutical Industries Limited, Zydus Lifesciences Ltd, Laurus Labs Ltd, Cipla Limited, Dr.Reddys Lab, Aurobindo Pharma Ltd., Mankind Pharma, Lupin Ltd, among others.
By market capitalisation, the largest Medicinal Chemicals and Botanical Products companies are Sun Pharmaceutical Industries Limited (₹4,21,995 Cr), Zydus Lifesciences Ltd (₹1,12,020 Cr), Laurus Labs Ltd (₹1,11,310 Cr), Cipla Limited (₹1,07,048 Cr), Dr.Reddys Lab (₹1,02,611 Cr).
The 86 Medicinal Chemicals and Botanical Products companies tracked on FinBizNet have a combined market capitalisation of about ₹16,39,750 Cr.
The median price-to-earnings ratio across 71 profitable Medicinal Chemicals and Botanical Products companies is 32.9, and the median return on equity across the industry is 10.2%. Medians are shown for context only.
FinBizNet aggregates broker research, sub-industry breakdowns, quarterly results and peer-stock comparisons across the Medicinal Chemicals and Botanical Products industry.